In this section
In August 2017, the FDA approved the use of CAR T-cell therapy, a new type of immunotherapy for the treatment of B-cell acute lymphoblastic leukemia (ALL) in children and young adults. In April 2018 the FDA expanded the use of this therapy to patients 18 or older with Non-Hodgkin Lymphoma (NHL). The name of this treatment is KYMRIAH™.
Stock photo here - do not publish live
What is CAR T-cell therapy?
CAR-T therapy, or chimeric antigen receptor T-cell therapy, involves collecting a patient’s own T-cells from their blood and genetically modifying those cells to recognize and destroy cancer cells. After these cells are modified in the lab, they are infused into the patient as a living drug. The modified anti-cancer cells then work to attack a specific protein on leukemia or lymphoma cells.
This innovative therapy has shown great promise in curing previously incurable patients with both refractory (has never gone into remission) and relapsed (has previously gone into remission, but later recurred) acute ALL and NHL.
What is KYMRIAH™ and who can benefit from it?
KYMRIAH™ is a cell-based prescription drug made from a patient’s own blood cells. It is intended for patients aged 25 and under who have either relapsed or refractory ALL.
The FDA recently expanded the use of KYMRIAH™ to include patients 18 and older with certain forms of relapsed or refractory NHL.
Why choose Children's Hospital of Wisconsin?
Children’s Hospital of Wisconsin is one of the few hospitals certified to administer KYMRIAH™.
This certification is supported by our decades of experience in immunotherapy and blood and marrow transplantation. Our extensive expertise managing patients throughout highly complex cancer treatment protocols makes Children’s Hospital of Wisconsin a leader in the care of children with the most difficult to treat cases of cancer.
How soon can your child be seen?
At Children’s Hospital of Wisconsin, we understand that cancer treatment requires a swift response. During the intake process, we will work closely with you, your child’s referring physician, and your insurance company to expedite the process and ensure a smooth transition for your child.